Abstract |
A comparative open study was performed to evaluate the efficacy of single doses of ciprofloxacin (500 mg) and trimethoprim-sulfamethoxazole ( TMP-SMZ; 640 mg/3,200 mg) for the treatment of culture-proven chancroid. Clinical cure or improvement was observed 7 days after treatment in 32 (76.2%) of the 42 patients who received ciprofloxacin and 21 (52.5%) of the 40 patients who received TMP-SMZ (P = .04). Cultures for one (4.5%) of 22 patients not cured with ciprofloxacin and 16 (59.3%) of 27 patients not cured with TMP-SMZ were still positive for Haemophilus ducreyi 7 days after treatment (P < .001). Although 77 (71.3%) of the 108 patients tested were seropositive for HIV-1 antibody, HIV infection and the degree of CD4+ lymphocyte depletion had no effect on clinical and bacteriologic outcome. All isolates of H. ducreyi were highly susceptible to ciprofloxacin (MIC, 0.004-0.06 mg/L). In contrast, resistance to TMP-SMZ (MIC, > or = 4/76 micrograms/mL) was observed in 48.9% of isolates (22 of 45) and was significantly associated with treatment failure. Therefore, the administration of TMP-SMZ, in single or multiple doses, is no longer indicated for the treatment of chancroid in Rwanda.
|
Authors | J Bogaerts, L Kestens, W Martinez Tello, J Akingeneye, V Mukantabana, J Verhaegen, E Van Dyck, P Piot |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 20
Issue 4
Pg. 924-30
(Apr 1995)
ISSN: 1058-4838 [Print] United States |
PMID | 7795096
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Ciprofloxacin
- Trimethoprim, Sulfamethoxazole Drug Combination
|
Topics |
- Adult
- CD4 Lymphocyte Count
- Chancroid
(blood, complications, drug therapy)
- Ciprofloxacin
(pharmacology, therapeutic use)
- Drug Resistance, Microbial
- Female
- Follow-Up Studies
- HIV Infections
(complications)
- Haemophilus ducreyi
(drug effects)
- Humans
- Male
- Microbial Sensitivity Tests
- Rwanda
- Treatment Failure
- Trimethoprim, Sulfamethoxazole Drug Combination
(pharmacology, therapeutic use)
|